CEL-SCI CORP. was formed to acquire and finance research and development of natural human interleukin-2 (``IL-2``) and lymphokine-related products and processes using the Co.'s proprietary cell culture technologies. The Co.'s proprietary product is sometimes referred to as MULTIKINEn, or buffy-coat interleukins, which is a combination, or ``cocktail`` of IL-2 and certain lymphokines and cytokines. MULTIKINE is a trade name of Co. Since its inception the focus of the Co.'s product development efforts has been on conducting clinical trials to test its proprietary technologies.
| Revenue (Most Recent Fiscal Year) | -- |
| Net Income (Most Recent Fiscal Year) | $-32.19M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | -- |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 2.66 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -- |
| Net Margin (Trailing 12 Months) | -- |
| Return on Equity (Trailing 12 Months) | -239.31% |
| Return on Assets (Trailing 12 Months) | -102.69% |
| Current Ratio (Most Recent Fiscal Quarter) | 0.64 |
| Quick Ratio (Most Recent Fiscal Quarter) | 0.18 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 1.00 |
| Inventory Turnover (Trailing 12 Months) | 0.00 |
| Book Value per Share (Most Recent Fiscal Quarter) | $0.28 |
| Earnings per Share (Most Recent Fiscal Quarter) | -- |
| Earnings per Share (Most Recent Fiscal Year) | $-0.73 |
| Diluted Earnings per Share (Trailing 12 Months) | $-0.58 |
| Exchange | NYSEMKT |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 66.39M |
| Free Float | 55.61M |
| Market Capitalization | $27.55M |
| Average Volume (Last 20 Days) | 1.81M |
| Beta (Past 60 Months) | 0.65 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 16.24% |
| Percentage Held By Institutions (Latest 13F Reports) | 12.08% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |